SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 55.15+2.5%Jan 5 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Sam Citron who wrote (11925)6/5/2004 12:39:58 PM
From: scaram(o)uche  Read Replies (2) of 52153
 
milestone and royalty depend on what the biotech wants to do, how flush they are, etc. in this case, IDEV wants to build a sales team asap and they weren't flush, so the milestone was huge and the royalty decent.

there are no guidelines. if you're in control of a late-stage project, then you generally go for a big royalty and co-marketing, placing less emphasis on milestone. but there are real world needs and objectives that can drive a deal to the opposite spectrum, and Pliva was willing to wrap lots of potential revenue around a big cash bolus.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News